— Know what they know.
Not Investment Advice

YMAB NASDAQ

Y-mAbs Therapeutics, Inc.
1W: +0.3% 1M: +1.1% 3M: +74.3% 1Y: -35.0% 3Y: -47.2% 5Y: -79.7%
$8.61
Last traded 2025-09-16 — delisted
NASDAQ · Healthcare · Biotechnology · $391.2M mcap · 34M float · 2.62% daily turnover · Short 55% of daily vol

📊 Key Metrics

TTM
$85M
Revenue
-1.3% YoY
$-22M
Net Income
+9.7% YoY
$-18M
Free Cash Flow
-42.8% YoY
86.4%
Gross Margin
-28.7%
Op. Margin
-16.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-24.3%
ROA-17.0%
ROIC-74.3%

Valuation

P/E-12.9
P/B4.1
EV/EBITDA-5.8

Leverage

Debt/Equity0.04
Current Ratio4.00
Interest Cov.0.0x

Quality Scores

Piotroski F4/9
Altman Z-1.00
Beneish M-3.01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms